Get in touch about GlobalData Company reports
Contact the team or request a demo to find out how our data can drive your business forward
Related keylists
Laurus Labs Ltd (Laurus Labs) is a research-driven pharmaceutical manufacturing organization. Its products include active pharmaceutical ingredients and intermediates, finished dosages, non-human ingredients. The company also offers rare disease therapeutics drugs comprise trientine tetrahydrochloride and lasinone. Laurus Labs offers research and development services including drug substance development services, drug product development services, biologics development services. It also provides custom development and manufacture of animal health ingredients, agrochemical ingredients, generic active pharmaceutical ingredients (APIs) and proprietary active pharmaceutical ingredients (APIs), intermediates. The company's products serve a wide range of applications in healthcare, nutrition, and personal care industries. Laurus Labs is headquartered in Hyderabad, Telangana, India.
Headquarters
India
Address
Plot No. 103, Road No. 1, Jubilee Hills, Hyderabad, Telangana, 500034
Website
www.lauruslabs.com
Telephone
91 40 39804333
No of Employees
7,059
Industry
Pharmaceuticals and Healthcare
Ticker Symbol & Exchange
LAURUSLABS (NSE)
Revenue (2025)
$781.9M
10.2%
(2025 vs 2024)
EPS
XYZ
Net Income (2025)
XYZ
123.2%
(2025 vs 2024)
Market Cap*
$8.6B
Net Profit Margin (2024)
XYZ
102.8%
(2025 vs 2024)
* As of and is in US$
Products and Services
| Products | Services | Brands |
|---|---|---|
| Pharmaceutical Ingredients | Drug Substance Development | TriLaWil |
| Finished Dosages | Drug Product Development | |
| Non-Human Ingredients | Biologics Development |
History
History section provides information on new products, mergers, acquisitions, expansions, approvals, and many more key events.
| Year | Event | Description |
|---|---|---|
| 2025 | Financing Agreements | In October, the company invested in Aarvik Therapeutics. |
| 2025 | Plans/Strategy | In July, the company announced its plans to invest up to EUR5 million in its joint venture, KRKA Pharma. |
| 2025 | Regulatory Approval | In March, the company's board of director approved to invest INR83.30 crore in its joint venture with KRKA. |
Competitor Comparison
| Key Parameters | Laurus Labs Ltd | Dr. Reddy's Laboratories Ltd | Aurobindo Pharma Ltd | Piramal Pharma Ltd | Granules India Ltd |
|---|---|---|---|---|---|
| Headquarters | India | India | India | India | India |
| City | Hyderabad | Hyderabad | Hyderabad | Mumbai | Hyderabad |
| State/Province | Telangana | Telangana | Telangana | Maharashtra | Telangana |
| No. of Employees | 7,059 | 27,527 | 9,107 | 7,126 | 4,066 |
| Entity Type | Public | Public | Public | Public | Public |
Key Financial Charts
Sales Growth
Net Income Growth
Executives
| Name | Position | Board | Since | Age |
|---|---|---|---|---|
| Ravindranath Kancherla | Chairman | Executive Board | 2017 | - |
| Krishna Chaitanya Chava | Director | Executive Board | 2024 | - |
| Satyanarayana Chava | Executive Director; Chief Executive Officer | Senior Management | 2006 | - |
| V. V. Ravi Kumar | Executive Director; Chief Financial Officer | Senior Management | - | - |
| Ch. Sita Ramaiah | Executive Vice President - Finance | Senior Management | - | - |
| Non Dignissim Eros | Proin vel | Convallis | 2026 | XY |
| Non Dignissim Eros | Proin vel | Convallis | 2026 | XY |
| Non Dignissim Eros | Proin vel | Convallis | 2026 | XY |
Still looking?
Have you found what you were looking for? From start-ups to market leaders, uncover what they do and how they do it.
Explorer
Access more premium companies when you subscribe to Explorer